Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of patients with symptomatic Waldenström macroglobulinemia finds cumulative SPM incidence 4.0% and 7.2% at 5 and 10 yrs; transformation to high-grade NHL accounting for death from WM or other cause at 5 and 10 yrs was 2.1% and 3.4%.”
Title: Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia
Authors: Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Charalampos Filippatos, Marie Christine Kyrtsonis, Nikolaos Giannakoulas, Emmanouil Spanoudakis, Sosanna Delimpasi, Michalis Michael, Stavroula Giannouli, Georgia Kaiafa, Eirini Katodritou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis
You can read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.
More posts featuring Robert Orlowski.
